Practical Considerations for Treating Patients With Cancer in the COVID-19 Pandemic

Author:

Segelov Eva1,Underhill Craig2,Prenen Hans3,Karapetis Christos4,Jackson Christopher5,Nott Louise6,Clay Tim7,Pavlakis Nick8,Sabesan Sabe9,Heywood Ellen10,Steer Christopher2,Lethborg Carrie11,Gan Hui K.121314,Yip Desmond15,Karanth Narayan16,Karikios Deme17,MacIntyre C. Raina18

Affiliation:

1. Department of Oncology, Monash University and Monash Health, Melbourne, Victoria, Australia

2. Border Medical Oncology, Albury-Wodonga Regional Cancer Centre, and University of NSW Rural Clinical School, Albury Campus, Albury, New South Wales, Australia

3. Department of Oncology, University Hospital Antwerp, Edegem, Belgium

4. Department of Medical Oncology, Flinders Medical Centre, Flinders University, Adelaide, South Australia, Australia

5. Department of Medicine, University of Otago, Dunedin, New Zealand

6. Department of Medical Oncology, Royal Hobart Hospital, Hobart, Tasmania, Australia

7. Department of Oncology, St John of God Subiaco Hospital and School of Medicine and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia

8. Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia

9. Department of Medical Oncology, Townsville Cancer Centre, Townsville Hospital and Health Services, Townsville, Queensland, Australia

10. Cancer Services, Monash Health, Melbourne, Victoria, Australia

11. Inclusive Health Research, St Vincent’s Health Australia, Melbourne, Victoria, Australia

12. Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Victoria, Australia

13. La Trobe University School of Cancer Medicine, Heidelberg, Victoria, Australia

14. Department of Medicine, University of Melbourne, Heidelberg, Victoria, Australia

15. Department of Medical Oncology, The Canberra Hospital and ANU Medical School, Australian National University, Canberra, Australian Capital Territory, Australia

16. Department of Medicine, Royal Darwin Hospital, Darwin, Northern Territory, Australia

17. Department of Medical Oncology, Nepean Hospital and Nepean Clinical School, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia

18. Biosecurity Program, Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia

Abstract

Cancer has become a prevalent disease, affecting millions of new patients globally each year. The COVID-19 pandemic is having far-reaching impacts around the world, causing substantial disruptions to health and health care systems that are likely to last for a prolonged period. Early data have suggested that having cancer is a significant risk factor for mortality from severe COVID-19. A diverse group of medical oncologists met to formulate detailed practical advice on systemic anticancer treatments during this crisis. In the context of broad principles, issues including risks of treatment, principles of prioritizing resources, treatment of elderly patients, and psychosocial impact are discussed. Detailed treatment advice and options are given at a tumor stream level. We must maintain care for patients with cancer as best we can and recognize that COVID-19 poses a significant competing risk for death that changes conventional treatment paradigms.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Oncology (nursing),Health Policy,Oncology

Cited by 49 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3